VPT Share Price | VentriPoint Diagnostics Ltd. Stock Analysis & Recommendation

Results Declared: VentriPoint Diagnostics Ltd. has declared results on 01 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

413.73 k

Shareholding (Sep 2012)

FII

0.12%

Held by 1 FIIs

DII

99.88%

Held by 0 DIIs

Promoter

0.00%

Compare VentriPoint Diagnostics Ltd. with Similar Stocks

FuelPositive Corp.Ocumetics Technology Corp.Covalon Technologies Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 19 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.47

Return on Equity

87.50%

Price to Book

-4.03

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

8.33%

6 Months

36.84%

1 Year

-7.14%

2 Years

-48.0%

3 Years

-3.7%

4 Years

-56.67%

5 Years

-71.74%

VentriPoint Diagnostics Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.66%

EBIT Growth (5y)

-143.90%

EBIT to Interest (avg)

-3.89

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.46

Sales to Capital Employed (avg)

-0.04

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.12%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-4.63

EV to EBIT

-6.40

EV to EBITDA

-6.51

EV to Capital Employed

-9.60

EV to Sales

23.76

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2012

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.12%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 81.82% vs 8.33% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-1.00",
          "chgp": "30.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.20",
          "val2": "-1.10",
          "chgp": "81.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-171,609.00%",
          "val2": "0.00%",
          "chgp": "-17,160.90%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 100.00% vs 0.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 34.69% vs 0.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.30",
          "val2": "-4.70",
          "chgp": "29.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.20",
          "chgp": "150.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.20",
          "val2": "-4.90",
          "chgp": "34.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18,893.70%",
          "val2": "-50,454.10%",
          "chgp": "3,156.04%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.70

-1.00

30.00%

Interest

0.20

0.10

100.00%

Exceptional Items

0.00

Consolidate Net Profit

-0.20

-1.10

81.82%

Operating Profit Margin (Excl OI)

-171,609.00%

0.00%

-17,160.90%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 81.82% vs 8.33% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.20

0.10

100.00%

Operating Profit (PBDIT) excl Other Income

-3.30

-4.70

29.79%

Interest

0.50

0.20

150.00%

Exceptional Items

0.00

Consolidate Net Profit

-3.20

-4.90

34.69%

Operating Profit Margin (Excl OI)

-18,893.70%

-50,454.10%

3,156.04%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 100.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 34.69% vs 0.00% in Dec 2024

All Annual Results

Company CV

About VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd.

Pharmaceuticals & Biotechnology

Ventripoint Diagnostics Ltd., formerly Luca Capital Inc., is a medical device company. The Company is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. By using images produced from existing medical imaging systems, the Ventripoint Medical System (VMS) generates accurate heart volumetric measurements and a three-dimensional (3D) model in a rapid and inexpensive manner. The Company's solution produces critical heart information by processing standard information received from existing medical imaging equipment with its methods incorporating Knowledge Based Reconstruction (KBR) algorithms and cardiac databases (catalogues). Its technology platform is applicable to all heart diseases. The Company has developed prototype analytical software package to be used with 4D echocardiograms (VMS-4DE) and one to be used with magnetic resonance imaging (MRI) images (VMS-CMR). It also focuses on developing VMS-Plus and the VMS-Nano.

Company Coordinates

Company Details

2 Sheppard Ave E , NORTH YORK ON : M2N 5Y7

Tel: 1 416 8484156

https://www.ventripoint.com

Registrar Details